Axial3D has announced that its automated, artificial intelligence-driven medical segmentation platform is FDA cleared for orthopedic trauma, orthopaedic, maxillofacial, and cardiovascular applications.
“Our FDA clearance for Axial3D Insight is a testament to how far Axial3D has come,” Daniel Crawford, founder and chief strategy office of Axial3D, said in the release. “From our humble beginnings as a startup to now being recognized as a leading medical technology company, this achievement showcases our dedication to pushing the boundaries of
